- Home
- ASRT
as of 03-02-2026 3:36pm EST
$11.94
+$0.30
+2.58%
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | LAKE FOREST |
| Market Cap: | 76.0M | IPO Year: | 2004 |
| Target Price: | $35.00 | AVG Volume (30 days): | 33.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.19 | EPS Growth: | 95.07 |
| 52 Week Low/High: | $0.51 - $12.95 | Next Earning Date: | N/A |
| Revenue: | $124,961,000 | Revenue Growth: | -17.83% |
| Revenue Growth (this year): | -9.89% | Revenue Growth (next year): | 1.42% |
| P/E Ratio: | -61.26 | Index: | N/A |
| Free Cash Flow: | 26.4M | FCF Growth: | -34.85% |
AI-Powered ASRT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 70.40%
70.40%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Assertio Holdings Inc. News
ASRT Breaking Stock News: Dive into ASRT Ticker-Specific Updates for Smart Investing
Compare ASRT vs Leading Stocks
See how ASRT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ASRT Assertio Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.